Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: It has been suggested that soluble fms-like tyrosine kinase receptor-1 (sFlt-1) and placental growth factor (PlGF) play potential roles in preeclampsia diagnosis. Nevertheless, studies on the use of sFlt-1, PlGF, and sFlt-1/PlGF ratio in predicting preeclampsia have found contradictory results. Thus, more studies in different populations are needed.
Objectives: This study aims to (i) examine the associations between sFlt-1, PlGF, or sFlt-1/PlGF ratio at gestational ages of 24-28 weeks and subsequent preeclampsia, and (ii) estimate predictive values of these markers in southern Vietnamese women.
Methods: We used a nested case-control design from a cohort of 490 pregnant women who were at risk of preeclampsia. The total sample size for statistical analysis consisted of 30 cases and 67controls. Levels of sFlt-1 and PlGF were quantified by using a fully automated electrochemiluminescence immunoassay platform (Elecsys®/Cobas®).
Results: The median of sFlt-1 concentration was not statistically different between case and control groups. The median PlGF concentration was lower (349.7 pg/ml versus 534.6 pg/ml, P < .001) and the median sFlt-1/PlGF ratio was higher in the preeclampsia group (4.3 versus 1.9, P < .001). After adjusting for maternal age, gestational age, nullipara, and body mass index, the odds of preeclampsia in women with an sFlt-1/PlGF ratio in the fourth quartile were 10 times greater than in women with an sFlt-1/PlGF ratio in the other quartiles (95% confidence interval, 3.2-31.4; P < .001).
Conclusions: This study contributes to the literature that sFlt-1/PlGF ratio measured at gestational weeks 24-28 in southern Vietnamese women can separate preeclamptic from normotensive cases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.preghy.2018.07.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predicting first-trimester pregnancy outcome in threatened miscarriage: A comparison of a multivariate logistic regression and machine learning models.
Radiography (Lond)
September 2025
Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, Malta. Electronic address:
Introduction: Threatened miscarriage (TM), defined as first-trimester vaginal bleeding with a closed cervix and detectable fetal cardiac activity, affects up to 30 % of clinically recognised pregnancies and is linked to increased risk of adverse outcomes. This study evaluates the predictive value of first-trimester ultrasound (US) and biochemical (BC) markers in determining outcomes among women with TM symptoms.
Methods: This prospective cohort study recruited 118 women with viable singleton pregnancies (5 to 12 weeks' gestation) from Malta's national public hospital between January 2023 and June 2024.
HIF-1α-mediated inhibition of the sFlt-1/sENG/TNF-α pathway promotes angiogenesis to ameliorate pre-eclampsia.
J Mol Histol
September 2025
Department of Gynecology and Obstetrics, Yantaishan Hospital, Yantai, 264001, Shandong, China.
Pre-eclampsia (PE) is a common pregnancy complication, closely associated with endothelial dysfunction and inhibition of angiogenesis. This study aims to explore the pathological mechanisms causing endothelial dysfunction and suppressed angiogenesis in PE, with the aim of identifying potential drug targets. Human umbilical vein endothelial cells (HUVECs) were exposed to angiotensin II (Ang-II) to mimic PE-related endothelial dysfunction.
View Article and Find Full Text PDFDevelopment and validation of prediction model for pre-eclampsia-related maternal adverse outcome: retrospective cohort study.
Ultrasound Obstet Gynecol
August 2025
Department of Obstetrics and Gynecology, Women and Children's Hospital of Chongqing Medical University, Chongqing, China.
Objectives: Pre-eclampsia (PE) is a major contributor to maternal morbidity and mortality. This study aimed to identify clinical risk factors for maternal adverse outcome in women with PE, and to assess the time to event using predictive modeling.
Methods: This retrospective cohort study included women with a singleton pregnancy diagnosed with PE who received antenatal care between January 2019 and December 2023 at one of three hospitals in China.
Genomic Insights at the Maternal-Fetal Interface: Preeclampsia Subtypes and Clinical Implications.
Arterioscler Thromb Vasc Biol
August 2025
Division of Obstetrics and Gynecology Hadassah, Hebrew University Medical Center, Jerusalem, Israel (S.M.C., S.Y.).
Recent advances in single-cell transcriptomics have provided significant insights into the pathophysiology of preeclampsia, uncovering cell-type-specific gene expression changes at the maternal-fetal interface. Key discoveries include dysregulated angiogenic factors, such as elevated sFlt-1 (soluble fms-like tyrosine kinase-1) and reduced PlGF (placental growth factor), predominantly in syncytiotrophoblasts, alongside inflammatory and stress-related signatures in stromal and immune cells. These findings reinforce the clinically observed concept of 2 distinct preeclampsia subtypes: a placenta-dominant form and a maternal cardiovascular-dominant form, each characterized by unique etiologies, clinical presentations, and therapeutic implications.
View Article and Find Full Text PDFApplication of Serum sFlt-1/PlGF Ratio Combined with Uterine Artery Blood Flow Ultrasound in Predicting Early-Onset Preeclampsia.
Int J Womens Health
August 2025
Obstetrics Department, the Second Affiliated Hospital of Shandong First Medical University, Tai 'an, Shandong, 271000, People's Republic of China.
Objective: This study aimed to evaluate the predictive efficacy of combining serum soluble fms-like tyrosine kinase-1/placental growth factor (sFlt-1/PlGF) ratio with uterine artery Doppler ultrasound for early-onset preeclampsia (PE) before 34 weeks' gestation.
Methods: A retrospective cohort analysis was conducted on 148 singleton pregnancies (control group: n = 76; early-onset PE group: n = 72) who delivered at our institution between July 2023 and June 2024. At 24-28 weeks, serum sFlt-1 and PlGF levels were quantified via electrochemiluminescence immunoassay (Roche Elecsys), and uterine artery pulsatility index (PI), resistance index (RI), and systolic/diastolic ratio (S/D) were measured by Doppler ultrasound (M22 system, standardized settings).